

Pan American Health Organization Ethics Review Committee

2022 Annual Report

Abridged version, March 2023 (edited January, 30, 2024)







I. Overview

In 2022, PAHOERC continued to meet the challenges from the surge in research efforts that began in 2020 with the novel coronavirus pandemic and its increased demand for research ethics guidance and support. PAHOERC members, observers, and Secretariat responded to the research demands posed by two simultaneous health emergencies -- COVID-19 and mpox (monkeypox) -- while resuming the review of non-emergency-related research that had been stalled due to the pandemic.

PAHOERC received 102 proposals in 2022 through ProEthos, (PAHO-developed platform), which represent projects proposed for 28 countries and territories. PAHOERC convened 10 regular meetings and four auxiliary meetings in 2022 to review these; members also screened proposals, provided comments, completed reviews, and addressed numerous consultations by email. Twenty-seven proposals were related to COVID-19 and two were related to mpox. A salient topic of research conducted with the Organization's involvement in 2022 was the uptake of COVID-19 vaccines.

Many teams with no prior experience or training in research proposed projects involving research with human subjects in 2022, due to increased support for research, ample emergency-related research funding, and easily accessible research tools (e.g., online surveys). Ensuring the social and scientific value of these proposals – a necessary condition of ethical research-- required extensive support from PAHOERC. Ensuring all research with human subjects conducted with PAHO's technical or financial involvement adheres to ethical standards remains a high priority, as well as strengthening research capacities across the Organization and the Region.

II. Summary of activities

A. Ensuring that human subjects research in which PAHO is involved meets ethical standards

PAHOERC received 102 submissions through its online portal in 2022, 99 of which were unique submissions (in English, Spanish, Portuguese, and French) proposed for the countries or territories listed below, multiple countries, or across the Latin America or Caribbean Subregions.

Honduras, 5 Perú, 5 Guyana, 4 Argentina, 7 Bolivia. Ecuador, 3 Paraguay, 3 Jamaica, 4 British Virgin Islands. Aruba Colombia, 16 Ecuador, 2 Chile, 6 Costa Rica, 1 Pana... Haiti, 1 Caribbean, 3 Mexico, 2 Cuba, Surina... Trinidad LAC, 28 Brazil, 8 Uruguay, 6 Dominica, 3 St. Lucia, 2

Countries represented by the 99 submissions to PAHOERC in 2022

All countries are represented here.


Of the 99 unique research proposals submitted to PAHOERC in 2022:

- 91 were screened by PAHOERC members to determine whether they were research projects with human subjects that required PAHOERC review.
- 58 were granted an exemption from full PAHOERC review in accordance with the criteria established by PAHOERC's SOPs.
- 32 were deemed research with human subjects thus requiring full review by the Committee or further action by the Secretariat.
- 28 were reviewed in full in 2022 during 14 meetings (including one amendment and one secondary review of a project submitted in 2021).
- 16 projects were approved for implementation in the Region.
- 7 of the 16 projects approved were related to COVID-19.

• 2 were related to mpox (including one non-research protocol for an unproven intervention to be offered outside of research under the monitored emergency use of unregistered and experimental interventions (MEURI) framework).

Fewer proposals were approved in 2022, although PAHOERC received and reviewed a similar number of proposals as in previous years. One possible reason is that many teams without prior research experience embarked on research projects, resulting in proposals that lacked complete methodology or other essential information. Some teams appeared to abandon such proposals after observations revealed additional work would be needed prior to proceeding.

Proposal submissions included 27 submissions of COVID-19-related projects and two on mpox, with fewer than average proposals on regular annual cluster projects.



Topical distribution of the 99 unique propProposals received by PAHOERC in 2022

PAHOERC Member and Observer Contributions

^{*}Nearly all of these were exempt from PAHOERC review

PAHOERC's Secretariat continued providing key support to PAHOERC in 2022, including screening proposals to determine their readiness for the Committee's review; reviewing revised protocols and responses to observations; and meeting with research teams to explain review processes and discuss the Committee's observations.

PAHOERC members and observers again showed remarkable commitment to their duties, ensuring all research in which the Organization is involved is ethical while juggling the demands of two health emergencies. Their duties included:

- Reviewing materials on tight deadlines, meeting virtually and/or preparing written comments, responding to follow-up requests from the Secretariat.
- Preparing for and attending four additional PAHOERC meetings to accommodate emergency-related protocols and amendments; reviewing emergent evidence related to COVID-19 and mpox.
- Meeting with research teams virtually, by request, to clarify the observations or provide detailed reviews of technical protocol components via email.
- Reviewing a proliferation of underdeveloped protocols proposed by professionals inexperienced in conducting research with human subjects.

Two new members were added to ensure quorum was consistently met. The Organization's virtual work environment allowed PAHOERC to add a new external member based in Brazil. Two new members will be added in 2023 to replace retiring members a new member will be sought from the Caribbean to enhance geographical representation.

B. Building capacity in research ethics

PAHOERC continues to build capacity in research ethics within the Organization and throughout the LAC Region in tandem with PAHO's Regional Program on Bioethics.

Trainings

In 2022, the PAHOERC prioritized capacity-building efforts that were part of a series, were coorganized with the national health authority, and were open to all research ethics committees in the country, which included:

- Regular training sessions delivered to Bolivia, Guatemala, Costa Rica, Panama, and Paraguay.
- In-depth training activities for Argentina, El Salvador, Mexico, and Peru.
- Training on ProEthos:
 - o For Costa Rica, Guatemala, Panama, and Paraguay.
 - Using a train-the-trainer model (Panama's national authority, research ethics committees in Ethiopia, and the WHO-ERC Secretariat).
 - o Through an animated video, produced in 2022 in English and Spanish.
- Training internal and external teams on the MEURI framework (emergency use of unproven interventions outside of research, prompted by the mpox outbreak), the topic of Chapter 5 in the *Catalyzing Ethical Research in Emergencies* guidance. Teams represented Bolivia, Costa Rica, El Salvador, Guatemala, Mexico, Panama, Paraguay, and Peru, and regionally via the Incident Management Support Teams (IMST).
- Capacity building efforts focused on the ethical challenges posed by the COVID-19 pandemic (addressed in PAHO's <u>Catalyzing Ethical Research in Emergencies. Ethics Guidance, Lessons Learned from the COVID-19 Pandemic, and Pending Agenda)</u>.
- Supporting the development of ethics training material for research in emergencies, as coeditor and co-author of a chapter on ethics review of an Oxford-led, WHO-funded casebook on COVID-19-related research ethics cases (in the process of publication).
- Responding to ethics consultations from internal and external teams on proposals in various stages of development.
- Convening PAHO personnel in above-mentioned regional and national activities.

C. Advancing ethical standards in research

In conjunction with the Regional Program on Bioethics, ethical standards in research were advanced in 2022 via:

• The publication <u>Catalyzing Ethical Research in Emergencies</u>. <u>Ethics Guidance</u>, <u>Lessons</u> <u>Learned from the COVID-19 Pandemic</u>, <u>and Pending Agenda</u> (in English, Spanish, Portuguese, and French), and its <u>summary</u>, which offers a revised and integrated version of the ethics guidance documents PAHO developed for research in emergency situations

during the COVID-19 outbreak, supplemented with lessons learned in the Region during the pandemic. Capacity-building activities around this publication included:

- A <u>regional dialogue on the above-mentioned publication</u>; and a subsequent <u>regional</u>
 <u>dialogue</u> that presented the final recommendations.
- O Presentation of the publication at global venues (World Congress of Bioethics (Basel, June 2022) and the Global Summit of National Ethics Committees (Lisbon, September 2022)), as well as numerous academic venues and most health authorities in the Region. This was followed by discussions about the specific actions that can be taken to implement its recommendations.
- Support for the use of the MEURI ethical framework in the context of the mpox outbreak -- Catalyzing Ethical Research outlines the ethical criteria and recommendations to implement MEURI -- which were developed by PAHO and adopted by WHO in their 2022 MEURI guidance.)

Additional capacity-building activities in 2022 included:

- Support to WHO for development of the tecovirimat MEURI protocol; to WHO-ERC Secretariat for its review; and to PAHO's mpox IMST to ensure the ethical use of unproven interventions for mpox outside of research.
- Advancing the inclusion of minors in research (collaboration with Multi-Regional Clinical Trials (MRTC) Center of Brigham and Women's Hospital and Harvard) through webinars on the inclusion of children in clinical trials and a panel entitled "It's only fair: including adolescents and youth in research," presented at the 2nd Caribbean Congress on Adolescent and Youth Health.
- Continuing to promote a systemic approach to research ethics in the Region using PAHOdeveloped indicators, including their publication in *The Lancet* and presentation to WHO's Regional Offices. The following advances in the regional landscape are underway as a result of this process and support:
 - El Salvador and Paraguay completed the development of a new research ethics law and national policy, respectively, that are currently undergoing approval processes;
 - o Bolivia prepared a draft national research ethics policy; and

- COMISCA formally adopted the PAHO-developed research ethics indicators to guide and assess the subregion's progress.
- Revising the PAHOERC SOPs to incorporate lessons learned from the COVID-19 pandemic and addressing issues covered by recent ethics guidance (e.g., MEURI protocols), which will be submitted for approval in 2023.
- Reaching out to PAHO staff via the intranet to generate discussion around the importance of adhering to ethical standards in human subjects research that involves online surveys.

D. Maintaining PAHOERC's institutional memory

2022 was the third year PAHOERC used BIREME-developed platform ProEthos for process facilitation and institutional recordkeeping and to conduct its work effectively. The Secretariat conducted additional testing and worked with BIREME to optimize the platform, which included modifications to meet WHO's new cybersecurity standards.

An abridged version of PAHOERC's 2022 annual report was developed at the request of the Deputy Director's Office and disseminated to a broader audience. PAHOERC continues to make updated lists of COVID-19 and mpox submissions available at www.paho.org/pahoerc.

III. Recommendations

- 1. Ensure stable funding of the Secretariat so PAHOERC can fulfill its corporate duties.
- 2. Complete the revision of the SOPs based on experience gained during the pandemic and develop updated guidance for research ethics committees.
- 3. Develop an organization-wide strategy to strengthen personnel's capacities in research.
- 4. Continue with in-house training on research ethics, prioritizing sessions focused on the most common issues encountered by PAHOERC when reviewing protocols.
- 5. Incorporate by reference WHO's "Code of Conduct for Responsible Research" and WHO's "Policy on Misconduct in Research" in the E-manual to advance adherence to ethical standards in research among PAHO personnel.
- 6. Continue operating under the emergency procedures and support the IMSTs as needed.
- 7. Continue supporting the implementation of ProEthos.
- 8. Disseminate PAHOERC's 2022 Annual Report and abridged version.

PAHOERC Members 2022

Ana Luciañez

Bernardo Nuche Berenguer

Carolina Chávez Cortes

Carla Saenz (Secretary)

Hannah Kurtis

Hernán Rodríguez González *

Jonás Gonseth-García

Lionel Gresh **

Lúcia Helena de Oliveira

Ludovic Reveiz (Vice President)

María Paz Ade (President)

Maristela Monteiro

Omar Sued

Pedro Ordúñez

Sergio Surugi de Siqueira (External

member) **

Vilma Gawryszewski ***

PAHOERC Observers

Christina Marsigli, Department of External Relations, Partnerships and Resource Mobilization Gabriela Gergely, Ethics Office Pamela Zúñiga, Office of the Legal Counsel Roberto Samayoa, Department of

PAHOERC Secretariat Support: Marcie Neil

- * Since June 2022.
- ** Since March 2022.

Procurement and Supply Management

*** Until March 2022.

Annex: 2022 Proposals submitted to PAHOERC

PAHOERC	Title	Countries	Department
ID			
612.01	Fortalecimiento de la articulación de equipos de	Argentina,	CDE
	trabajo en salud y ciencia para la optimización de	Colombia,	
	la vigilancia del virus linfotrópico T humano en	Chile,	
	Argentina, Colombia, Chile y Uruguay	Uruguay	
610.01	Acurácia de testes sorológicos rápidos para diagnóstico de leishmaniose visceral nas Américas	LAC	CDE
606.01	Rising immunity gaps in Latin America and the Caribbean due to COVID-19 and the effect on the elimination of vaccine preventable diseases	Caribbean	FPL
604.01	WHO Stepwise Survey - Aruba	Aruba	NMH
603.01	Proyecto de incorporación de componentes de telemedicina en la atención prenatal en sitios seleccionados de Honduras	Honduras	FPL/CLAP
601.01	Exploring the use of telehealth during the pandemic in the Americas	LAC	EIH

600.01	Evaluación de la respuesta clínica y tolerabilidad de intervenciones locales para el tratamiento de la leishmaniasis cutánea no complicada en Centro América y México (Protocolo para Panamá)	Panama	CDE
599.01	Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic	LAC	FPL
598.01	Estudio de la carga de mortalidad atribuible a las infecciones del torrente sangueneo con resistencias antimicrobianas en el Uruguay: implementación de la adaptación del protocolo de Sistema Mundial de Vigilancia de la Resistencia a los Antimicrobianos (GLASS)	Uruguay	CDE
597.01	Caracterización epidemiológica y molecular de la deficiencia de glucosa 6 fosfato deshidrogenasa (G6PD) en la población general de zonas endemicas a la malaria en Quibdó y sus alrededores, Departamento del Chocó, Colombia, octubre 2022- septiembre 2023.	Colombia	CDE
596.01	Elimination of leishmaniasis as a public health threat in Colombia: Ensuring access to essential health products	LAC	CDE
595.01	Evaluation of human resources for health technical cooperation	LAC	PBE
594.01	Estudio descriptivo sobre la experiencia de usuario durante la implementación de una aplicación de información sobre el cuidado neonatal	Uruguay	FPL/CLAP
593.01	Manual práctico de indicadores asociados a registros nominales de vacunación electrónicos	Bolivia	FPL
591.02	Primer estudio de salud mental para Bogotá	Colombia	HSS
590.01	Protocol: a prospective cohort study investigating maternal, pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-2. PregNeoCOVID Chilean three sites study	Chile	HSS
588.01	Proposta de intervenção diagnóstica em municípios com elevados indices de falha terapêutica da poliquimioterapia da hanseníase	Brazil	CDE
587.01	Evaluación del impacto de la vacunación contra la influenza en la carga de enfermedad severa asociada a los virus de influenza estacional en América Latina y el Caribe	LAC	FPL

586.01	COVID-19 vaccine effectiveness in children, adolescents, and pregnant women: A multi-country regional evaluation, 2021-2022.	LAC	FPL
585.01	Monkeypox vaccine effectiveness evaluation: Study protocol for Latin American and Caribbean countries	LAC	FPL
582.01	Sistematización de la experiencia acumulada del Departamento de Inmunizaciones en la vigilancia de eventos supuestamente atribuibles a vacunación e inmunización (ESAVI), Chile	Chile	FPL
581.01	Efeitos da pandemia pelo COVID-19 na população residente no município de Mossoró, no período de 2020 a 2022	Brazil	CDE
580.01	Diseño, conducción, analisis de datos y presentación de resultado de necesidades de capacitación en los vacunatorios, servicios de salud y secretarias regionales ministeriales (SEREMI) de Chile	Chile	FPL
578.01	Understanding health financing aspects in the provision of medicines in the Caribbean region	Caribbean	HSS
577.01	Mapeo de capacidades para el cuidado canguro en América Latina y El Caribe	Uruguay	FPL
575.01	Documentación del desarrollo del registro nacional de inmunizaciones	Chile	FPL
574.01	Caracterización de desafios y lecciones aprendidas en grupos y redes de familias de recién nacidos prematuros	Argentina	FPL/CLAP
572.01	Evaluation of PAHO's technical cooperation in non-communicable disease prevention and control in the Americas (ENCD TC) inception report	LAC	PBE
571.01	Identificación de barreras para la atención integral del aborto. Lecciones aprendidas a través de la Red CLAP MUSA	Brazil	FPL/CLAP
570.01	Impacto de la pandemia de COVID-19 en la atención de las mujeres en situación de aborto en América Latina y el Caribe	LAC	FPL
569.01	Primary health care and the COVID-19 pandemic case studies: Uruguay	Uruguay	HSS
568.01	Implementation of the IDA impact survey (IIS) to validate the elimination of lymphatic filariasis as a public health problem in Guyana	Guyana	CDE

567.01	Formative research to inform a public health campaign on the reduction of salt consumption	Caribbean	NMH
566.01	Emergency use protocol for tecovirimat for monkeypox under MEURI framework	LAC	PHE & EIH
565.01	Earmarking case study deep dive: Jamaica and Dominica	Jamaica, Dominica	NMH
564.01	Efeitos da pandemia pelo COVID-19 nos profissionais de saúde que trabalham na Secretaria Municipal de Saúde do município de Mossoró, no período de 2020 a 2022	Brazil	PHE
561.01	Aceptación de la vacunación contra la COVID-19 en poblaciones indídgenas en Colombia	Colombia	FPL
558.01	Monitoreo de políticas públicas	Argentina	FPL
557.02	Prácticas de los servicios de inmunización COVID-19 en población migrante que accede a la prestación de salud en la macrozona norte de Chile	Chile	HSS & FPL
555.01	WHO EIOS implementation evaluation 2022	LAC	PHE & EIH
554.01	YouthSpeak360: A digital mechanism to deliver and collect health information from youth in the Latin America-Caribbean Region	LAC	FPL
553.01	Community health and primary care workers in the diagnosis and control of non-communicable diseases in the Caribbean in the COVID-19 context	LAC	HSS
552.01	Surveillance: Healthcare workers survey	LAC	HSS & PHE
551.01	Antibiotic consumption in Colombian intensive care units and other wards: national surveillance from 2018-2020	Colombia	CDE
550.01	Implementación del programa de vacunación para los trabajadores de salud, Ministerio de Salud de la Nación, República Argentina. Un estudio de caso	Argentina, Paraguay	FPL
549.01	High levels of antimicrobial resistance in Escherichia coli and Salmonella from poultry in Ecuador	Ecuador	CDE
547.01	Encuesta y evaluación del impacto de intervenciones orientadas a la reducción de la desnutrición crónica en menores de 24 meses de edad de las provincias de Pichincha, Imbabura,	Ecuador	NMH

	Bolívar, Santa Elena, Esmeraldas, Pastaza y Morona de Santiago durante julio de 2022 y junio de 2024		
546.01	Descripción de los eventos adversos fetales y neonatales en mujeres inmunizadas con vacunas COVID-19 durante el embarazo en la red CLAP. Análisis caso-control anidado en una cohorte del riesgo asociado con la inmunización	LAC	HSS & FPL
545.01	High level of infection prevention and control performance in surveyed hospitals of Colombia during 2021	Colombia	CDE
543.01	Operational research protocol for the diagnosis of tuberculosis, histoplasmosis, and cryptococcosis in people with advanced HIV disease using rapid, point-of -care tests	LAC	CDE
542.02	Factor influencing COVID-19 vaccine uptake among older adults in Jamaica	Jamaica	NMH
541.01	Redes de apoyo para mujeres indígenas adolescentes en Costa Rica	Costa Rica	HSS
538.01	Piloting a rapid service assessment tool to review and improve post-rape care for women survivors of sexual violence	Peru, Colombia, Paraguay	NMH
537.01	Encuesta serológica de Pian en áreas seleccionadas de Ecuador	Ecuador	CDE
536.01	COVID-19 vaccination of persons with disabilities	LAC	NMH
532.01	Programmatic assessment of vaccine provider perspectives on barriers to Yellow Fever (YF) vaccination in South American countries	Bolivia, Ecuador, Guyana, Peru, Suriname	FPL
531.01	Evaluation of PAHO's response to COVID-19 (EPRC)	LAC	PBE
530.01	Contextual diagnosis for the awareness campaign for vaccination against COVID-19 among nursing and pregnant women	Jamaica	NMH
528.01	Pesquisa qualitativa sobre propostas inovadoras de regionalização dos serviços assistenciais do SUS	Brazil	HSS

527.03	Social marketing Risk Communication and Community Engagement Campaign (RCCE) promotion of lifetime vaccine uptake	Grenada, Jamaica, St. Lucia, St. Vincent and the Grenadines	NMH
525.01	Encuesta de línea de base para estimar la prevalencia de tracoma en población de unidades de evaluación seleccionadas en estados priorizados de Venezuela	Venezuela	CDE
524.01	Assessment of implementation and effectiveness of HEARTS technical package	St. Lucia, British Virgin Islands, Dominica	NMH
523.01	Implementation of the lateral flow urine lipoarabinomannan (LF-LAM) assay for the detection of active Tuberculosis (TB) in people living with advanced HIV disease in Trinidad and Tobago	Trinidad and Tobago	CDE
522.01	Encuesta nacional de lactancia (ENaLac) – 2022	Argentina	FPL
521.01	Mapeo de normativas relacionados con las acciones de prevención, vigilancia y control de la influenza y otros virus respiratorios con potencial epidémico y pandémico	LAC	PHE
520.02	Rapid community assessments among healthcare workers in the Caribbean	Dominica	FPL
519.01	Impacto del diagnostico rápido y temprano de contactos de casos con tuberculosis en la etapa de eliminacion de la enfermedad en Cuba	Cuba	CDE
518.01	Epidemiology and distribution pattern of cutaneous Leishmaniasis in Guyana: a surveillance study	Guyana	CDE
517.01	Diagnóstico comunicacional sobre conocimientos, actitudes, prácticas, aciertos y barreras relacionadas a la promoción de la vacunación contra la COVID-19 para mayores de 18 años en Moquegua y Tacna (Perú)	Peru	FPL
515.01	Designing a rapid response program to support EIDM in health emergencies: using the best available evidence and case studies from the COVID-19 response	LAC	EIH

514.01	Estudio multicéntrico sobre la implementación de políticas integrales de aborto en América Latina	Argentina, Colombia, Honduras, Mexico, Uruguay	FPL/CLAP
513.02	Pilotage d'un programme de dépistage du SARS-CoV-2 dans une cohorte de travailleurs de santé, Haïti, Juin-Juillet 2022	Haiti	PHE
512.01	Diagnosis and identification of leishmania species in patients with cutaneous leishmaniasis in Guyana	Guyana	CDE
509.01	Feasibility study of the priority indicators for adolescent health measurement proposed by the Global Action for Measurement of Adolescent Health (GAMA) advisory group	LAC	NMH
507.01	Eventos adversos posteriores a la vacunación covid-19 en población vacunada en la Subred Integrada de Servicios de Salud Norte E.S.E.	Colombia	HSS
506.01	National antimicrobial consumption evaluation for the year 2020, Latin America and the Caribbean	LAC	CDE
505.01	Primaquina doble dosis para la cura radical de plasmodium vivax, un ensayo controlado aleatorizado en Colombia	Colombia	CDE
503.01	Surveillance Protocol for cefiderocol and other drugs susceptibility in carbapenem-resistant organisms in Latin America and the Caribbean 2021-2022	LAC	CDE
501.01	Accessible and inclusive vaccine delivery for people with disabilities	LAC	NMH
500.01	Mapeo de percepciones sobre la comunicación de riesgo en la respuesta a la pandemia por la COVID-19 y estrategias para fortalecer los laboratorios de comunicación de riesgos	Mexico	PHE
498.01	Documentación sistemáica de la introducción de vacunas contra COVID-19 en países seleccionados de Latinoamérica y el Caribe (LAC): lecciones aprendidas	LAC	FPL
497.01	Pesquisa de avaliabilidade da política nacional de promoção da saúde	Brazil	NMH
496.02	Yellow fever vaccine neutralizing antibody response four to seven years after vaccination in Argentinian children vaccinated at 12 to 13 months of age	Argentina	FPL

495.01	Psychological first aid course for Barbadian first responders and the wider community: A course proposal	Barbados	NMH
493.01	Comunicación en salud para promover la vacunación contra la COVID-19 en comunidades indígenas del departamento de Nariño, Colombia	Colombia	FPL
492.01	Anáisis de políticas del componente de salud y desarrollo de los adolescentes en Colombia, Ecuador y Perú	Colombia, Ecuador, Peru	HSS
490.01	STEPS Survey	Paraguay	NMH
488.01	Consulta para desarrollo de documento de políticas sobre atracción, captación y retención de recursos humanos para la salud en áreas remotas, rurales y urbanas desatendidas	LAC	HSS
486.01	Impacto de la campaña nacional de comunicación de la vacuna contra la COVID-19 "Vacúnate ya", Honduras; marzo 2022	Honduras	HSS
485.01	As práticas de prevenção primária e secundaria de câncer de colo uterino e seus familiares em pernambuco	Brazil	CDE
484.02	Eficácia do VDOT na adesão ao tratamento de curta duração (3HP) para a tuberculose latente em migrantes em Manaus, Amazonas	Brazil	CDE
483.03	Estudio de métodos mixtos sobre la higiene facial y su relación con el tracoma y la higiene bucal en Alto Amazonas, Perú	Perú	CDE
482.03	Coinfección con microorganismos respiratorios en pacientes con infección por SARS-COV-2 en la ciudad de Bogotá D.C.	Colombia	FPL
481.01	Factors associated with adherence to clinical guidelines in prescribing amoxicillin for community-acquired pneumonia in children under 5 in ambulatory settings, Colombia, 2017-2019	Colombia	CDE
479.02	Mediadores socioculturales que intervienen en la implementación del lavado facial en población indígena de 1 a 9 años de las áreas endémicas para tracoma, Vaupés, Amazonía colombiana	Colombia	CDE
478.01	Antimicrobial susceptibility profiles in Escherichia coli and Salmonella spp. isolated from animal feed in Colombia, 2018-2021	Colombia	CDE
477.01	Eficácia, imunogenicidade e segurança da vacina inativada (Coronavac) contra SARS-CoV-2 em crianças e adolescente	Brazil	FPL

476.03	Oportunidades perdidas de vacunación contra la COVID-19, Honduras, febrero 2022	FPL
467.02	Anticoncepción post evento obstétrico en Honduras adolescentes	HSS